[go: up one dir, main page]

ES2659519T3 - Método para producir medicamentos para combatir tumores - Google Patents

Método para producir medicamentos para combatir tumores Download PDF

Info

Publication number
ES2659519T3
ES2659519T3 ES12005995.1T ES12005995T ES2659519T3 ES 2659519 T3 ES2659519 T3 ES 2659519T3 ES 12005995 T ES12005995 T ES 12005995T ES 2659519 T3 ES2659519 T3 ES 2659519T3
Authority
ES
Spain
Prior art keywords
hla
tumor
antibodies
expression profile
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12005995.1T
Other languages
English (en)
Inventor
Wolfgang Würfel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2659519T3 publication Critical patent/ES2659519T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Método de producción de un medicamento para combatir un tumor en un huésped, que comprende - determinar el perfil de expresión de HLA embrionario individual de una célula tumoral del tumor en una muestra del paciente, incluyendo el perfil de expresión de HLA la expresión de genes menores de HLA-E, HLA-F y HLA-G de clase I, - desarrollar anticuerpos contra el perfil de expresión y - acoplar los anticuerpos con una citotoxina, tal como un agente quimioterápico o un radioisótopo, en el que los anticuerpos individuales así creados sirven como medicamento antitumoral y/o los anticuerpos van a usarse para destruir el perfil de HLA embrionario específico del tumor.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
ES12005995.1T 2011-08-25 2012-08-22 Método para producir medicamentos para combatir tumores Active ES2659519T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011111631 2011-08-25
DE102011111631A DE102011111631A1 (de) 2011-08-25 2011-08-25 Verfahren zur Herstellung von Medikamenten zur Tumorbekämpfung

Publications (1)

Publication Number Publication Date
ES2659519T3 true ES2659519T3 (es) 2018-03-16

Family

ID=46826183

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17001634T Active ES2959600T3 (es) 2011-08-25 2012-08-22 Método para producir medicamentos para combatir tumores
ES12005995.1T Active ES2659519T3 (es) 2011-08-25 2012-08-22 Método para producir medicamentos para combatir tumores

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES17001634T Active ES2959600T3 (es) 2011-08-25 2012-08-22 Método para producir medicamentos para combatir tumores

Country Status (5)

Country Link
EP (2) EP2561890B1 (es)
DE (1) DE102011111631A1 (es)
DK (2) DK3284479T3 (es)
ES (2) ES2959600T3 (es)
FI (1) FI3284479T3 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017001875A1 (de) * 2017-02-27 2018-08-30 Wolfgang Würfel Medikament zur Malignombehandlung
DE102017005815A1 (de) * 2017-06-20 2018-12-20 Wolfgang Würfel Vakzine zur Behandlung eines Malignoms
US20210238690A1 (en) * 2018-04-26 2021-08-05 Intellexon Gmbh Hla-j and medical/diagnostic uses thereof
JP2022540090A (ja) * 2019-07-05 2022-09-14 インテレクソン・ゲーエムベーハー 個人のｈｌａパターンの決定、予後因子としての使用、標的遺伝子、及び治療薬
EP4048815A1 (en) 2019-10-25 2022-08-31 Intellexon GmbH Hla-h, hla-j, hla-l, hla-v and hla-y as therapeutic and diagnostic targets
AU2020371899A1 (en) 2019-10-25 2022-05-19 Intellexon Gmbh HLA class I molecules in in vitro fertilization and further medical implications

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003012544A (ja) * 2001-03-27 2003-01-15 Kouji Egawa 癌予防・治療剤
JP5525689B2 (ja) * 2004-11-02 2014-06-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 過剰増殖性障害を処置するための組成物および方法

Also Published As

Publication number Publication date
EP3284479A1 (en) 2018-02-21
EP2561890B1 (en) 2017-11-15
DK2561890T3 (da) 2018-01-29
FI3284479T3 (fi) 2023-09-06
DK3284479T3 (da) 2023-09-18
EP2561890A1 (en) 2013-02-27
EP3284479B1 (en) 2023-06-07
DE102011111631A1 (de) 2013-02-28
ES2959600T3 (es) 2024-02-27

Similar Documents

Publication Publication Date Title
ES2659519T3 (es) Método para producir medicamentos para combatir tumores
PH12017501576B1 (en) Riluzole prodrugs and their use
CL2017001943A1 (es) Terapias de combinación para el tratamiento de cánceres
CL2017002996A1 (es) Compuestos alqueno tetrasustituidos y su uso
CR20160018A (es) Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc)
BR112017011536A2 (pt) terapias de combinação
DOP2015000100A (es) Inhibidores de la tirosina-quinasa de bruton
CR20160203A (es) Inhibidores de tirosina cinasa de bruton
MX2022013713A (es) Combinaciones anticancer de un agente antihialuronato y un taxano orientado a tumor.
AR088391A1 (es) Fitocanabinoides para usar en el tratamiento de cancer de mama
BR112015004875A2 (pt) formulações de anticorpo e seus usos
BR112016002646A2 (pt) dispositivos e métodos de entrega de fármaco de múltiplas unidades
UY36075A (es) Derivados de tubulisina
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
ECSP20000655A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
NI201500150A (es) TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método
MX2015017959A (es) Composiciones y metodos para inmunoterapia.
CL2015002692A1 (es) Novedosos compuestos de bencenosulfonamida, método para sintetizarlos y uso de los compuestos en medicina y en cosméticos.
NI201500063A (es) Tratamiento de cáncer con pomalidomida en un individuo con daño renal
BR112018010066A8 (pt) Agente estimulante do receptor 5-hidroxitriptamina 1b para intensificar potencial de enxerto in vivo
DOP2010000327A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento de nivel de creatinina debido a la administracion de dronedarona
CL2016000397A1 (es) Tratamiento contra el cáncer
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
EP4233536A3 (en) Method for enhancing tumor growth
MX2016002502A (es) Composiciones farmaceuticas de bendamustina.